Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ranibizumab

Ranibizumab Reactions 1704, p330 - 2 Jun 2018 Intraocular pressure elevation: 8 case reports In a retrospective study, eight patients (four men and four women), aged 65 84 years, were described, who developed elevated intraocular pressure (IOP) following the administration of ranibizumab [Lucentis] for age-related macular degeneration (AMD). The patients with AMD received intravitreal ranibizumab 0.5mg in 0.05mL injections. The patients had a history of glaucoma (four patients) and ocular hypertension (one patient). After three to eight injections over three to twelve months, seven patients experienced IOP elevation, and one patient developed IOP elevation at four follow-up. The patients were treated with acetazolamide, brimonidine/ timolol, apraclonidine, brimonidine and/or pilocarpine. Six patient underwent selective laser trabeculoplasty, trabeculectomy, cyclodiode laser surgery or combined phacoemulsification and viscocanalostomy. After the procedure, their IOP had improved. Six patients were continued on ranibizumab injections after the procedure and their IOP remained controlled. Author comment: "Intravitreal ranibizumab injections are associated with sustained [intraocular pressure] elevation in some eyes." Reis GMSM, et al. Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration. Journal of Current Glaucoma Practice 11: 3-7, No. 1, Jan-Apr 2017. Available from: URL: http://doi.org/10.5005/jp-journals-10008-1213 - Australia 803323602 0114-9954/18/1704-0001/$14.95 Adis © 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ranibizumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Ranibizumab

Abstract

Reactions 1704, p330 - 2 Jun 2018 Intraocular pressure elevation: 8 case reports In a retrospective study, eight patients (four men and four women), aged 65 84 years, were described, who developed elevated intraocular pressure (IOP) following the administration of ranibizumab [Lucentis] for age-related macular degeneration (AMD). The patients with AMD received intravitreal ranibizumab 0.5mg in 0.05mL injections. The patients had a history of glaucoma (four patients) and ocular hypertension...
Loading next page...
 
/lp/springer_journal/ranibizumab-EBoxkWT2Ri
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46973-z
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p330 - 2 Jun 2018 Intraocular pressure elevation: 8 case reports In a retrospective study, eight patients (four men and four women), aged 65 84 years, were described, who developed elevated intraocular pressure (IOP) following the administration of ranibizumab [Lucentis] for age-related macular degeneration (AMD). The patients with AMD received intravitreal ranibizumab 0.5mg in 0.05mL injections. The patients had a history of glaucoma (four patients) and ocular hypertension (one patient). After three to eight injections over three to twelve months, seven patients experienced IOP elevation, and one patient developed IOP elevation at four follow-up. The patients were treated with acetazolamide, brimonidine/ timolol, apraclonidine, brimonidine and/or pilocarpine. Six patient underwent selective laser trabeculoplasty, trabeculectomy, cyclodiode laser surgery or combined phacoemulsification and viscocanalostomy. After the procedure, their IOP had improved. Six patients were continued on ranibizumab injections after the procedure and their IOP remained controlled. Author comment: "Intravitreal ranibizumab injections are associated with sustained [intraocular pressure] elevation in some eyes." Reis GMSM, et al. Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration. Journal of Current Glaucoma Practice 11: 3-7, No. 1, Jan-Apr 2017. Available from: URL: http://doi.org/10.5005/jp-journals-10008-1213 - Australia 803323602 0114-9954/18/1704-0001/$14.95 Adis © 2018

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.